Toshiaki Irie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Toshiaki Irie has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
Kiyoshi Fukushi
15 shared publicationsTatsuya Kikuchi
6 shared publicationsAkiyo Aotsuka
4 shared publications- Hitoshi Shinotoh
Advanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST), Chiba, Japan
4 shared publications Koichi Sato
4 shared publicationsShuji Tanada
National Institute of Radiological Sciences, Chiba, Japan
4 shared publications
Latest Publications
- 1 July 2013
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 40 (5) , 664-669
Non-input analysis for incomplete trapping irreversible tracer with PET
- 1 July 2013
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 40 (5) , 664-669
Non-input analysis for incomplete trapping irreversible tracer with PET
- 1 February 2012
- Published by Elsevier in NeuroImage
- Vol. 59 (4) , 3149-3158
A short-scan method for k3 estimation with moderately reversible PET ligands: Application of irreversible model to early-phase PET data
- 1 February 2012
- Published by Elsevier in NeuroImage
- Vol. 59 (4) , 3149-3158
A short-scan method for k3 estimation with moderately reversible PET ligands: Application of irreversible model to early-phase PET data
- 1 June 2011
- Published by Elsevier in NeuroImage
- Vol. 56 (3) , 1105-1110
Effect of radiolabeled metabolite elimination from the brain on the accuracy of cerebral enzyme activity estimation using positron emission tomography with substrate tracers
- 1 June 2011
- Published by Elsevier in NeuroImage
- Vol. 56 (3) , 1105-1110
Effect of radiolabeled metabolite elimination from the brain on the accuracy of cerebral enzyme activity estimation using positron emission tomography with substrate tracers
- 31 December 2010
- Published by Elsevier in Neuroscience Research
- Vol. 68, e193
Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET
- 31 December 2010
- Published by Elsevier in Neuroscience Research
- Vol. 68, e193
Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET
- 31 December 2009
- Published by Elsevier in Neuroscience Research
- Vol. 65, S117
Cortical amyloid deposition in Lewy body diseases with dementia demonstrated by PET
- 31 December 2009
- Published by Elsevier in Neuroscience Research
- Vol. 65, S117
Cortical amyloid deposition in Lewy body diseases with dementia demonstrated by PET
- 5 June 2009
- Published by Elsevier in Life Sciences
- Vol. 84 (23-24) , 791-795
A radiotracer method to study efflux transport of iodide liberated from thyroid hormones via deiodination metabolism in the brain
- 5 June 2009
- Published by Elsevier in Life Sciences
- Vol. 84 (23-24) , 791-795
A radiotracer method to study efflux transport of iodide liberated from thyroid hormones via deiodination metabolism in the brain
- Open Access
- 5 November 2008
- Published by SAGE Publications in Journal of Cerebral Blood Flow & Metabolism
- Vol. 29 (3) , 504-511
Noninvasive and Quantitative Assessment of the Function of Multidrug Resistance-Associated Protein 1 in the Living Brain
Multidrug resistance-associated protein 1 (MRP1) acts as a defense mechanism by pumping xenobiotics and endogenous metabolites out of the brain. The currently available techniques for studying brain-to-blood efflux have significant limitations related to either their invasiveness or the qualitative assessment. Here, we describe an in vivo method, which overcomes these limitations for assessing MRP1 function, using positron emission tomography (PET) and a PET probe. 6-Bromo-7-[11C]methylpurine was designed to readily enter the brain after intravenous administration and to be efficiently converted to its glutathione conjugate (MRP1 substrate) in situ. Dynamic PET scan provided the brain time—activity curve after injection of 6-bromo-7-[11C]methylpurine into mice. The efflux rate of the substrate was kinetically estimated to be 1.4 h−1with high precision. Moreover, knockout of Mrp1 gene caused approximately a 90% reduction of the efflux rate, compared with wild-type mice. In conclusion, our method allows noninvasive and quantitative assessment for MRP1 function in the living brain.
- 5 November 2008
- Published by SAGE Publications in Journal of Cerebral Blood Flow & Metabolism
- Vol. 29 (3) , 504-511
Open AccessNoninvasive and Quantitative Assessment of the Function of Multidrug Resistance-Associated Protein 1 in the Living Brain
Multidrug resistance-associated protein 1 (MRP1) acts as a defense mechanism by pumping xenobiotics and endogenous metabolites out of the brain. The currently available techniques for studying brain-to-blood efflux have significant limitations related to either their invasiveness or the qualitative assessment. Here, we describe an in vivo method, which overcomes these limitations for assessing MRP1 function, using positron emission tomography (PET) and a PET probe. 6-Bromo-7-[11C]methylpurine was designed to readily enter the brain after intravenous administration and to be efficiently converted to its glutathione conjugate (MRP1 substrate) in situ. Dynamic PET scan provided the brain time—activity curve after injection of 6-bromo-7-[11C]methylpurine into mice. The efflux rate of the substrate was kinetically estimated to be 1.4 h−1with high precision. Moreover, knockout of Mrp1 gene caused approximately a 90% reduction of the efflux rate, compared with wild-type mice. In conclusion, our method allows noninvasive and quantitative assessment for MRP1 function in the living brain.
- 15 April 2008
- Published by Wiley in Movement Disorders
- Vol. 23 (8) , 1154-1160
PET study of brain acetylcholinesterase in cerebellar degenerative disorders
To elucidate characteristic changes of brain acetylcholinesterase (AChE) in cerebellar degenerative disorders. Eight patients with the cerebellar variant of multiple system atrophy (MSA‐C), 7 patients with spinocerebellar ataxia type‐3 (SCA‐3), 3 patients with SCA‐6, and 13 healthy age‐matched volunteers participated in this study. Brain AChE activity was measured by [11C] N‐methylpiperidin‐4‐yl propionate PET in all subjects. Brain AChE activities were significantly decreased in the thalamus (−27%) and the posterior lobe of cerebellar cortex (−36%) in patients with MSA‐C and in the thalamus (−23%) in patients with SCA‐3 compared with healthy controls (P < 0.01). Thalamic AChE activities of SCA‐3 patients were negatively correlated with the unified Parkinson's disease rating scale motor subscore (P < 0.001). AChE activities were not significantly altered in the cerebral cortex in any disease group. Reduction of AChE activities in the thalamus and cerebellum in MSA and in the thalamus in SCA‐3 suggest that cholinergic modulating drugs may have a role in the treatment of ataxia and other symptoms in these disorders. © 2008 Movement Disorder Society
- 15 April 2008
- Published by Wiley in Movement Disorders
- Vol. 23 (8) , 1154-1160
PET study of brain acetylcholinesterase in cerebellar degenerative disorders
To elucidate characteristic changes of brain acetylcholinesterase (AChE) in cerebellar degenerative disorders. Eight patients with the cerebellar variant of multiple system atrophy (MSA‐C), 7 patients with spinocerebellar ataxia type‐3 (SCA‐3), 3 patients with SCA‐6, and 13 healthy age‐matched volunteers participated in this study. Brain AChE activity was measured by [11C] N‐methylpiperidin‐4‐yl propionate PET in all subjects. Brain AChE activities were significantly decreased in the thalamus (−27%) and the posterior lobe of cerebellar cortex (−36%) in patients with MSA‐C and in the thalamus (−23%) in patients with SCA‐3 compared with healthy controls (P < 0.01). Thalamic AChE activities of SCA‐3 patients were negatively correlated with the unified Parkinson's disease rating scale motor subscore (P < 0.001). AChE activities were not significantly altered in the cerebral cortex in any disease group. Reduction of AChE activities in the thalamus and cerebellum in MSA and in the thalamus in SCA‐3 suggest that cholinergic modulating drugs may have a role in the treatment of ataxia and other symptoms in these disorders. © 2008 Movement Disorder Society
- 23 February 2007
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 15 (9) , 3127-3133
A novel noninvasive method for assessing glutathione-conjugate efflux systems in the brain
- 23 February 2007
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 15 (9) , 3127-3133
A novel noninvasive method for assessing glutathione-conjugate efflux systems in the brain
- 1 October 2006
- Vol. 47 (10) , 1717-22
Evaluation of 4'-[methyl-14C]thiothymidine for in vivo DNA synthesis imaging.
We evaluated 4'-[methyl-11C]thiothymidine ([methyl-11C]S-dThd) to obtain a thymidine analog that might prove simpler to use for imaging DNA synthesis and that might follow the same biochemistry as its surrogate. [Methyl-14C]S-dThd was synthesized by rapid methylation of 5-trimethylstannyl-4'-thio-2'-deoxyuridine via a palladium-mediated Stille coupling reaction with 14C-methyl iodide. Degradation of [methyl-14C]S-dThd, when incubated in human blood, was analyzed by high-performance liquid chromatography (HPLC). The in vivo potential of [methyl-14C]S-dThd was evaluated by studying its distribution in EMT-6 mammary carcinoma-bearing mice. 2-Fluoro-2'-deoxycytidine, a potent inhibitor of DNA synthesis, was used to modulate cell proliferation. Tissue extraction was also performed to investigate the incorporation of [methyl-14C]S-dThd into DNA. [Methyl-14C]S-dThd was obtained in a 31%-41% radiochemical yield (calculated from 14C-methyl iodide) at 130 degrees C, 5-min reaction in N,N-dimethylformamide followed by semipreparative HPLC purification. The radiochemical purity of [methyl-14C]S-dThd was >99% and the specific activity was 2.04 GBq/mmol (according to the specific activity of 14C-methyl iodide). [2-14C]Thymidine, when incubated with human blood, demonstrated rapid degradation. In contrast, [methyl-14C]S-dThd was stable with <3% degradation at 60 min. An in vivo distribution study showed the accumulation of radioactivity in proliferating tissues (spleen, thymus, duodenum, and tumor). On the other hand, the radioactivity of nonproliferating tissues (lung, liver, kidney, and muscle) was rapidly cleared in parallel with the clearance of blood radioactivity. The tumor uptake of [methyl-14C]S-dThd was high (8.8 percentage injected dose per gram at 60 min) and selective (tumor-to-blood ratio, 12.2 at 60 min). 2-Fluoro-2'-deoxycytidine pretreatment significantly reduced the tumor uptake of [methyl-14C]S-dThd. Relative blood flow as measured by the uptake of 4-[N-methyl-14C]iodoantipyrine was similar between the treated and untreated groups. Tissue extraction studies showed that most of the total tissue radioactivity of rapidly proliferating tissues was recovered in the DNA fraction at 60 min after [methyl-14C]S-dThd injection. The labeling procedure is rapid and suitable for 11C labeling. Positron-labeled 4'-thiothymidine should be useful for imaging DNA synthesis by PET.
- 1 October 2006
- Vol. 47 (10) , 1717-22
Evaluation of 4'-[methyl-14C]thiothymidine for in vivo DNA synthesis imaging.
We evaluated 4'-[methyl-11C]thiothymidine ([methyl-11C]S-dThd) to obtain a thymidine analog that might prove simpler to use for imaging DNA synthesis and that might follow the same biochemistry as its surrogate. [Methyl-14C]S-dThd was synthesized by rapid methylation of 5-trimethylstannyl-4'-thio-2'-deoxyuridine via a palladium-mediated Stille coupling reaction with 14C-methyl iodide. Degradation of [methyl-14C]S-dThd, when incubated in human blood, was analyzed by high-performance liquid chromatography (HPLC). The in vivo potential of [methyl-14C]S-dThd was evaluated by studying its distribution in EMT-6 mammary carcinoma-bearing mice. 2-Fluoro-2'-deoxycytidine, a potent inhibitor of DNA synthesis, was used to modulate cell proliferation. Tissue extraction was also performed to investigate the incorporation of [methyl-14C]S-dThd into DNA. [Methyl-14C]S-dThd was obtained in a 31%-41% radiochemical yield (calculated from 14C-methyl iodide) at 130 degrees C, 5-min reaction in N,N-dimethylformamide followed by semipreparative HPLC purification. The radiochemical purity of [methyl-14C]S-dThd was >99% and the specific activity was 2.04 GBq/mmol (according to the specific activity of 14C-methyl iodide). [2-14C]Thymidine, when incubated with human blood, demonstrated rapid degradation. In contrast, [methyl-14C]S-dThd was stable with <3% degradation at 60 min. An in vivo distribution study showed the accumulation of radioactivity in proliferating tissues (spleen, thymus, duodenum, and tumor). On the other hand, the radioactivity of nonproliferating tissues (lung, liver, kidney, and muscle) was rapidly cleared in parallel with the clearance of blood radioactivity. The tumor uptake of [methyl-14C]S-dThd was high (8.8 percentage injected dose per gram at 60 min) and selective (tumor-to-blood ratio, 12.2 at 60 min). 2-Fluoro-2'-deoxycytidine pretreatment significantly reduced the tumor uptake of [methyl-14C]S-dThd. Relative blood flow as measured by the uptake of 4-[N-methyl-14C]iodoantipyrine was similar between the treated and untreated groups. Tissue extraction studies showed that most of the total tissue radioactivity of rapidly proliferating tissues was recovered in the DNA fraction at 60 min after [methyl-14C]S-dThd injection. The labeling procedure is rapid and suitable for 11C labeling. Positron-labeled 4'-thiothymidine should be useful for imaging DNA synthesis by PET.